Market disruption across pharmaceutics, alcohol, prisons, and new Cannabis-driven industries.
The move to Schedule III didn’t settle the argument over Cannabis medicine — it spotlighted it. Two pathways still define the future: patented pharmaceuticals or the herbal gold standard. A dual‑track system where one pathway is federally empowered, while the other remains structurally constrained.
Public trust in leadership is declining globally. Awareness of corporate concentration, lobbying power, and regulatory capture is rising. Cannabis policy sits at the intersection of all three. This is no longer simply a debate about health or legality; it has become a broader issue.
Bad laws didn’t just criminalise a drug — they sidelined a carbon‑negative plant that can undeniably support food security, local energy, soil health, and community resilience. This post unpacks how political fiction, corporate control, and outdated THC limits locked up the wrong plant in the climate debate.
THC limits in hemp don’t just affect farmers — they shape global energy, agriculture, and bio-diesel futures. Can rational regulation unlock hemp’s full potential?
